273 related articles for article (PubMed ID: 30587523)
1. Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.
de Queiroz NMGP; Xia T; Konno H; Barber GN
Mol Cancer Res; 2019 Apr; 17(4):974-986. PubMed ID: 30587523
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
Xia T; Konno H; Barber GN
Cancer Res; 2016 Nov; 76(22):6747-6759. PubMed ID: 27680683
[TBL] [Abstract][Full Text] [Related]
3. C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells.
Morimoto D; Matsumura S; Bustos-Villalobos I; Sibal PA; Ichinose T; Naoe Y; Eissa IR; Abdelmoneim M; Mukoyama N; Miyajima N; Tanaka M; Kodera Y; Kasuya H
Cells; 2021 Jun; 10(6):. PubMed ID: 34203706
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
Hong B; Chapa V; Saini U; Modgil P; Cohn DE; He G; Siddik ZH; Sood AK; Yan Y; Selvendiran K; Pei G; Zhao Z; Yoo JY; Kaur B
Clin Cancer Res; 2021 Jan; 27(2):542-553. PubMed ID: 33087329
[TBL] [Abstract][Full Text] [Related]
5. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer.
Fujiwara S; Nawa A; Luo C; Kamakura M; Goshima F; Kondo C; Kiyono T; Kikkawa F; Nishiyama Y
Cancer Gene Ther; 2011 Feb; 18(2):77-86. PubMed ID: 20885447
[TBL] [Abstract][Full Text] [Related]
6. Defining a murine ovarian cancer model for the evaluation of conditionally-replicative adenovirus (CRAd) virotherapy agents.
González-Pastor R; Ashshi AM; El-Shemi AG; Dmitriev IP; Kashentseva EA; Lu ZH; Goedegebuure SP; Podhajcer OL; Curiel DT
J Ovarian Res; 2019 Feb; 12(1):18. PubMed ID: 30767772
[TBL] [Abstract][Full Text] [Related]
7. STING activator 2'3'-cGAMP enhanced HSV-1-based oncolytic viral therapy.
Sibal PA; Matsumura S; Ichinose T; Bustos-Villalobos I; Morimoto D; Eissa IR; Abdelmoneim M; Aboalela MAM; Mukoyama N; Tanaka M; Naoe Y; Kasuya H
Mol Oncol; 2024 May; 18(5):1259-1277. PubMed ID: 38400597
[TBL] [Abstract][Full Text] [Related]
8. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
9. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
10. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.
Salako MA; Kulbe H; Ingemarsdotter CK; Pirlo KJ; Williams SL; Lockley M; Balkwill FR; McNeish IA
Mol Ther; 2011 Mar; 19(3):490-9. PubMed ID: 21081903
[TBL] [Abstract][Full Text] [Related]
12. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
[TBL] [Abstract][Full Text] [Related]
13. Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
Tong JG; Valdes YR; Sivapragasam M; Barrett JW; Bell JC; Stojdl D; DiMattia GE; Shepherd TG
BMC Cancer; 2017 Aug; 17(1):594. PubMed ID: 28854921
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
15. Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of
Froechlich G; Caiazza C; Gentile C; D'Alise AM; De Lucia M; Langone F; Leoni G; Cotugno G; Scisciola V; Nicosia A; Scarselli E; Mallardo M; Sasso E; Zambrano N
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33213060
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
17. The cGas-Sting Signaling Pathway Is Required for the Innate Immune Response Against Ectromelia Virus.
Cheng WY; He XB; Jia HJ; Chen GH; Jin QW; Long ZL; Jing ZZ
Front Immunol; 2018; 9():1297. PubMed ID: 29963044
[TBL] [Abstract][Full Text] [Related]
18. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
19. Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis.
Sasso E; Froechlich G; Cotugno G; D'Alise AM; Gentile C; Bignone V; De Lucia M; Petrovic B; Campadelli-Fiume G; Scarselli E; Nicosia A; Zambrano N
Sci Rep; 2020 Mar; 10(1):4307. PubMed ID: 32152425
[TBL] [Abstract][Full Text] [Related]
20. STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy.
Arwert EN; Milford EL; Rullan A; Derzsi S; Hooper S; Kato T; Mansfield D; Melcher A; Harrington KJ; Sahai E
Nat Cell Biol; 2020 Jul; 22(7):758-766. PubMed ID: 32483388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
